Skip to main content

Table 1 Basic information of included studies

From: Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials

No

Author

Year

Sites

Start and End

Treatment Plan

Subjects

Pathogen Detected at Baseline

OMC

LZD

OMC

LZD

OMC

LZD

1

Gary J. Noel

2012

11 sites in the USA

2007.07–2008.01

100 mg (i.v.) q24h/200 mg (p.o.) q24h

a600 mg (i.v.) q12h/600 mg (p.o.) q12h

118

116

G+ pathogen:

S. aureus: 72

MRSA: 44

MSSA:\

G+ bacterium other than S. aureus: 3

G+ Pathogen:

S. aureus: 55

MRSA: 32

MSSA:\

G+ bacterium other than S. aureus: 7

2

NCT00865280

\

7 sites in the USA

2009.04–2010.04

100 mg (i.v.) q24h/300 mg (p.o.) q24h

b600 mg (i.v.) q12h/600 mg (p.o.) q12h

70

73

\

\

3

William O’Riordan (OASIS-1)

2019

55 sites in the USA, Peru, South Africa, and Europe

2015.06–2016.05

100 mg (i.v.) q12h for 1 day + 100 mg (i.v.) q24h for 2 days + 100 mg (i.v.) or 300 mg (p.o.) q24h

600 mg (i.v.) q12h for 3 days + 600 mg (i.v.) or 600 mg (p.o.) q12h

323

322

Mono-G+: 156

Poly-G+: 31

Mixed: 41

G+ Pathogen:

S. aureus: 156

MRSA: 69

MSSA: 88

S. pyogenes: 11

Streptococcus anginosis group: 47

E. faecalis: 10

Mono-G+: 171

Poly-G+: 27

Mixed: 29

G+ Pathogen:

S. aureus: 151

MRSA: 50

MSSA: 102

S. pyogenes: 18

Streptococcus anginosis group: 37

E. faecalis: 13

4

William O’Riordan (OASIS-2)

2019

33 sites in the USA

2016.08–2017.06

450 mg (p.o.) q24h for 2 days + 300 mg (p.o.) q24h

600 mg (p.o.) q12h for 2 days + 600 mg (p.o.) q12h

368

367

Mono-G+: 184

Poly-G+: 60

Mixed: 32

G+ Pathogen:

S. aureus: 220

MRSA: 104

MSSA: 120

S. pyogenes: 29

Streptococcus anginosis group: 57

E. faecalis: 7

Mono-G+: 212

Poly-G+: 37

Mixed: 38

G+ Pathogen:

S. aureus: 233

MRSA: 107

MSSA: 130

S. pyogenes: 16

Streptococcus anginosis group: 45

E. faecalis: 10

No

Author

Note

Quality score

Infection types

Size of lesion

Drainage Procedures

Cellulitis/Erysipelas

Major abscess

Wound infection

1

Gary J. Noel

cOMC 8 (7%) LZD 10 (9%)

cOMC 73 (66%) LZD 72 (67%)

cOMC 21 (19%) LZD 17 (16%)

gAbscesses: OMC 12.6 cm; LZD 11.3 cm Wound infection: 13.6 cm

Incision and drainage of the infected site in all abscess patients is permitted before or within 24 h after treatment

4

2

NCT00865280

dOMC 39 (57%) LZD 45 (63%)

\

dOMC 13 (19%) LZD 13 (18%)

\

\

3

3

William O’Riordan (OASIS-1)

eOMC 123 (39%) LZD 118 (38%)

eOMC 91 (29%) LZD 89 (29%)

eOMC 102 (32%) LZD 104 (33%)

hOMC 299.5 (77 ~ 4100) cm2; LZD 315.0 (88 ~ 6739) cm2

Patients with major abscesses had allowed drainage procedures before (or within 48 h following) the first dose

5

4

William O’Riordan (OASIS-2)

fOMC 86 (24%) LZD 84 (23%)

fOMC 64 (18%) LZD 62 (17%)

fOMC 210 (58%) LZD 214 (59%)

hOMC 322 (198 ~ 495) cm2; LZD 294 (190 ~ 462) cm2

Patients with major abscesses had allowed drainage procedures before (or within 48 h following) the first dose

5

  1. S. aureus Staphylococcus aureus, MRSA meticillin-resistant S. aureus, MSSA meticillin-susceptible S. aureus, S. pyogenes, Streptococcus pyogenes, Streptococcus anginosis group: includes S. anginosus, Streptococcus intermedius, and Streptococcus constellatus, E.faecalis Enterococcus faecalis
  2. Mono-G+: monomicrobial Gram-positive infection; Poly-G+: polymicrobial Gram-positive infection; Mixed: polymicrobial Gram-positive and Gram-negative infection
  3. awith or without aztreonam
  4. b-with moxifloxacin
  5. cin intent-to-treat population, n = 111 and 108
  6. din clinically evaluable population, n = 68 and 72
  7. ein modified intent-to-treat population, n = 316 and 311
  8. fin modified intent-to-treat population, n = 360 and 360
  9. gmean maximum dimension
  10. hmean maximal linear dimension
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us